Skip to content
Peptigraph home

Tesamorelin Side Effects: What Studies and Users Report

What FDA labels, clinical studies and people who use Tesamorelin report, how strong that evidence is, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated

Side effects reported in studies

Adverse reactions from the FDA label come first, then side effects reported in individual studies. Frequencies are quoted as the source gives them; animal results are labelled.

Side effects of Tesamorelin in labels and published studies
Side effectHow commonStudy typeSource
Most commonly reported adverse reactionsmost commonFDA labelFDA label (Egrifta WR)
Diabetes (HbA1c 6.5% or higher)5% vs 1% (EGRIFTA vs placebo)FDA labelFDA label (Egrifta WR)
Injection site reaction17% vs 6% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Arthralgia13% vs 11% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Pain in extremity6% vs 5% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Myalgia6% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Peripheral edema6% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Paresthesia5% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Hypoesthesia4% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Rash4% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Dyspepsia2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Musculoskeletal pain2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Pain2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Pruritus2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Vomiting3% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Musculoskeletal stiffness2% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Blood creatine phosphokinase increased1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Carpal tunnel syndrome1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Joint swelling1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Muscle strain1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Night sweats1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Palpitations1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta WR)
Diabetes (HbA1c 6.5% or higher)5% vs 1% (EGRIFTA vs placebo)FDA labelFDA label (Egrifta SV)
Injection site reaction17% vs 6% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Arthralgia13% vs 11% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Pain in extremity6% vs 5% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Myalgia6% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Peripheral edema6% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Paresthesia5% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Hypoesthesia4% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Rash4% vs 2% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Dyspepsia2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Musculoskeletal pain2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Pain2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Pruritus2% vs 1% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Vomiting3% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Musculoskeletal stiffness2% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Blood creatine phosphokinase increased1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Carpal tunnel syndrome1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)
Joint swelling1% vs 0% (EGRIFTA vs placebo, 26 weeks)FDA labelFDA label (Egrifta SV)

Showing the first 40 of 51 rows, strongest sources first.

Overall safety findings

What studies said about safety as a whole, without naming a specific effect.

Overall safety findings for Tesamorelin in published studies
FindingHow commonStudy typeSource
Adverse events“There were no serious adverse events or differences in adverse events between the groups.”Frequency not statedHuman RCTn = 60The Journal of clinical endocrinology and metabolism 2012, PMID 23015655
Adverse events68% tesamorelin vs 36% placeboHuman RCTn = 152Archives of neurology 2012, PMID 22869065
Tolerability“The drug was well tolerated.”Frequency not statedHuman RCTn = 404Journal of acquired immune deficiency syndromes 2010, PMID 20101189
Withdrawal because of adverse event“Adverse events did not differ significantly between the two study groups, but more patients in the tesamorelin group withdrew from the study because of an adverse event.”Frequency not statedHuman RCTn = 412The New England journal of medicine 2007, PMID 18057338
Arthralgiastatistically significant (GH-axis drugs as a group)Systematic reviewn = 1511HIV medicine 2011, PMID 21265979
Oedemastatistically significant (GH-axis drugs as a group)Systematic reviewn = 1511HIV medicine 2011, PMID 21265979
Liver and kidney findings, anaemia and clinical chemistry changes (dogs)reversible; dogs onlyAnimal · rat and dog (not a human result)Basic & clinical pharmacology & toxicology 2007, PMID 17214611

What users report

Anecdotal evidence, 0 of 4

Side effects people describe from their own use of Tesamorelin, quoted from 14 Reddit threads we read in r/Tesamorelin, r/Peptides and r/PeptideGuide (searched 11 Oct 2026). Each count is the number of different people in those threads, not how common the effect is. These reports are unverified: products bought outside a pharmacy are often mislabelled or impure, and many people take several compounds at once.

Side effects people report from using Tesamorelin
What people noticedPeople reporting itIn their words
Joint or muscle aches10“My knees and hips started aching after a week” r/Tesamorelin, May 2026“I got hip pain for a week.” r/Tesamorelin, May 2026
Trouble sleeping10“I take tesa nightly and it’s really fucked up my sleep my HRV my Rhr and my recovery” r/Tesamorelin, Jun 2026Also taking other compounds“but tesa fucked my sleep” r/Tesamorelin, Jun 2026
Allergic reaction (hives, itching all over, swelling)10“my whole body was red and covered in hives like mosquito bites everywhere. Then my tongue started swelling, harder to breathe” r/Tesamorelin, Oct 2026“Chest turned bright red and my stomach broke out in a rash.” r/Tesamorelin, Oct 2026
Water retention or puffiness9“Yes I got water weight retention weeks 3-4.” r/Tesamorelin, May 2026“I'm on week 2 and bloated” r/Tesamorelin, May 2026
Numbness, tingling or carpal-tunnel-type pain in hands8“Over the last several weeks I’ve developed increasingly noticeable numbness/tingling in both hands” r/Tesamorelin, Aug 2026“started to wake up couple of times in the night with numbness in my fingers” r/Tesamorelin, Aug 2026
Injection-site redness, itching or welts7“Would get some bad swelling from shots, would look like bug bites or get bad skin irritation.” r/Tesamorelin, Oct 2026“Previously I would get welts at injection sites that felt kinda itchy and hard for a few days under the skin.” r/Tesamorelin, Oct 2026
Tiredness or lethargy5“Tesamorelin made me feel like hell every day, so tired and cranky like I hadn’t slept in days.” r/Peptides, Mar 2026“In both cases I was ABSOLUTELY EXHAUSTED all day every day for the first 2-3 weeks.” r/Tesamorelin, Jun 2026
Racing heart or raised heart rate4“Skin flushing, heart racing, throat felt tight” r/Peptides, Mar 2026“Made my heart race” r/Peptides, Mar 2026
Injection-site pain3“1mg still burns during and afterwards for about 1 hour afterwards.” r/Tesamorelin, Jun 2026“it’s always burned after pinning” r/Tesamorelin, Jun 2026
Vivid dreams3“having incredible incredible vivid dreams” r/Tesamorelin, May 2026“weird uncomfortable dreams” r/Tesamorelin, Jun 2026
Higher blood sugar2“Blood sugar was 110 i began. It was 144 (fasting) this morning.” r/Tesamorelin, May 2026“it started messing with my blood sugar” r/Tesamorelin, Jun 2026
Brain fog1“Brain fog and feeling flat.” r/Tesamorelin, Jun 2026Also taking other compounds
Stomach upset1“I had a stomach issue too at first.” r/Tesamorelin, May 2026
Headache1“The headache and aches would subside with advil then return immediately.” r/Tesamorelin, Jun 2026
Fat loss in unwanted areas1“I’m starting to notice my boobs look like they’re losing fat too” r/Peptides, Aug 2026

3 people in the same threads said they noticed no side effects:

“No side effects but I’m seeing results with more defined abdomen.” r/Tesamorelin, May 2026“I loved Tesa when I ran it and had zero reactions.” r/Tesamorelin, Oct 2026

A symptom others mention is not proof that it is harmless. If you have anything on the urgent list below, get care whatever others report.

What is not known

  • How common each effect is at the doses people use outside of studies.
  • Effects that take longer to appear than the length of the published studies.
  • How Tesamorelin interacts with other medicines and supplements.
  • Whether research-grade products, which are not checked by the FDA, behave like the material used in studies.

When to get medical help

Get urgent care for: trouble breathing, swelling of the face or throat, a widespread rash, severe or lasting stomach pain, fainting, or an injection site that becomes hot, red and spreading.

This is not a complete list. A doctor or pharmacist can help you judge whether a symptom is related.

What the Egrifta label forbids

The label lists four contraindications: disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy.[1]

For pregnancy, the label reasons that modifying visceral adipose tissue offers no benefit and could result in fetal harm.[1]

Serious warnings in the label

The label lists increased risk of neoplasms: a preexisting malignancy should be inactive and its treatment complete before starting, and the drug should be discontinued if malignancy recurs.[1]

The label states that it stimulates GH production and increases serum IGF-1, a growth factor.[1]

The label says fluid retention may occur and may include edema, arthralgia and carpal tunnel syndrome.[1]

The label says glucose intolerance or diabetes mellitus may develop.[1]

Hypersensitivity reactions occurred in 4% of patients treated in clinical trials.[1]

What the HIV lipodystrophy trials reported

A large phase 3 trial found no significant difference in adverse events between arms, but more patients on tesamorelin withdrew because of an adverse event.[8]

In the 52-week extension, changes in glucose parameters were not clinically significant.[7]

A fatty-liver trial reported more localised injection-site complaints with tesamorelin, none judged serious.[3]

A recent meta-analysis of HIV lipodystrophy trials observed growth hormone-related adverse effects and higher discontinuation rates (RR2.25, p=0.06).[9]

Common questions

What are the side effects of Tesamorelin?

The FDA label lists most commonly reported adverse reactions, diabetes (hba1c 6.5% or higher), injection site reaction among others. The table on this page gives how often each happened and links each source.

What side effects do people who use Tesamorelin report?

In the 14 Reddit threads we read (11 Oct 2026), people most often described joint or muscle aches (10 people), trouble sleeping (10 people), allergic reaction (hives, itching all over, swelling) (10 people). These are unverified personal reports, often from products of unknown purity, and the counts are not rates.

Is tesamorelin safe?

One trial abstract in HIV patients with abdominal fat describes the drug as well tolerated. The label's contraindications and warnings are listed above.[6]

Is Tesamorelin banned in sport?

Yes. Prohibited by WADA (S2.2.4). Tested athletes should not use it.

What are the Egrifta side effects?

The label's most commonly reported adverse reactions were hypersensitivity reactions, edema-related reactions, hyperglycemia and injection site reactions.[1]

Does tesamorelin cause cancer?

The Egrifta WR label lists an increased risk of neoplasms as a warning: the drug induces release of growth hormone, a known growth factor, and it should not be used in patients with active malignancy.[1]

Can tesamorelin cause a rash?

Yes, rash is one of the hypersensitivity reactions the Egrifta WR label names, alongside itching, redness, flushing and hives; such reactions occurred in 4% of patients treated in clinical trials.[1]

More on Tesamorelin

Sources

  1. 1EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  2. 2EGRIFTA SV (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta SV), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  4. 4Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  5. 5Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Archives of neurology · 2012PMID 22869065Accessed 2 Oct 2026
  6. 6Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999) · 2010PMID 20101189Accessed 2 Oct 2026
  7. 7Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  8. 8Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  9. 9Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
  10. 10Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.HIV medicine · 2011PMID 21265979Accessed 11 Oct 2026
  11. 11Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.Basic & clinical pharmacology & toxicology · 2007PMID 17214611Accessed 11 Oct 2026
  12. 12Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  13. 13Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  14. 14Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  15. 15Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  16. 16Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  17. 17Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  18. 18Reddit thread in r/Peptides (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  19. 19Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  20. 20Reddit thread in r/Peptides (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026
  21. 21Reddit thread in r/Tesamorelin (user reports, unverified)Reddit, via the Arctic Shift archive · 2026reddit.comAccessed 11 Oct 2026

Found an error? Report a correction.